“Biogen is by far the worst-performing large-cap biotech stock of 2019 after the March failure of its key Alzheimer’s drug pushed its shares down more than 20 percent. Its first-quarter earnings results announced on Wednesday, while beating analysts’ profit estimates, did little to turn things around. A much-needed strategic shift was missing.”
Read the full story at washingtonpost.com
Biogen Stays the Wrong Course After a Key Drug Failure
More from BusinessMore posts in Business »
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ
- Braincheck Raises Another $1.5 Million to Bring Artificial Intelligence to Dementia Care | PR Web